内容概要：随着生物技术的飞速发展，数字PCR仪作为新一代的核酸检测技术，正逐渐在生命科学研 究、临床诊断、食品安全检测等领域崭露头角。数字PCR仪的出现，为核酸定量分析提供了更精确、更 灵敏的方法，弥补了传统PCR技术的一些局限性，被广泛认为是PCR技术发展的重要里程碑。在过去的 几年中，中国数字PCR仪市场规模呈现出稳健的增长态势。数据显示，2019-2025年中国数字PCR仪行 业市场规模从15.84亿元增长至88.15亿元，年复合增长率为33.1%。这一增长不仅得益于技术优势的驱 动，还得益于国家政策的支持。预计未来随着数字PCR仪的不断推广和应用，科研人员、临床医生以及 相关行业从业者对其优势和应用价值的认识逐渐加深，市场接受度不断提高，将进一步推动了市场需求 的增长。 相关上市企业：迈克生物（300463）、普门科技（688389）、科华生物（002022）、安图生物 （603658）、万孚生物（300482）、亚辉龙（688575）、美康生物（300439）、九强生物（300406）、 中源协和（600645）等。 相关企业：北京新羿生物科技有限公司、臻准生物科技（上海）有限公司、领航基因科技（杭 ...

证券日报网讯1月28日，中源协和（600645）在互动平台回答投资者提问时表示，VUM03注射液是为满 足临床局部使用需求而开发的通用现货型细胞制剂，于2025年3月获批IND，用于治疗非活动性/轻度活 动性克罗恩病复杂性肛瘘。后续如有其它申报项目，公司将依据信息披露规则要求及时披露。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：前期，北科生物干细胞治疗Ⅱ型糖尿病项目在海南博 鳌获批先行先试治疗，请问贵公司持有多少北科生物股权？北科生物近期是否有申请lPO？ 中源协和（600645.SH）1月28日在投资者互动平台表示，尊敬的投资者，您好。北科生物为公司参股 企业，公司持有其11.05%股份，是其众多股东之一，其具备自主经营能力，您可关注其官网等官方平 台发布信息。 ...

Core Viewpoint - The article highlights significant achievements and events within the China Shipbuilding Industry, including recognition, project completions, and internal meetings [2] Group 1 - China Shipbuilding Group's Zhihu account has been recognized as an influential government account for the year 2025 [2] - Guangzhou Shipyard International has successfully completed and delivered two vessels [2] - China Ship Asset Management (Beijing) held its 2026 annual work meeting and party building meeting [2] Group 2 - China Shipbuilding Industry held a collective birthday celebration for employees in January [2] - Waigaoqiao Shipbuilding welcomed the first snowfall of the winter season [2]

Core Viewpoint - The company, Zhongyuan Qihhe, has provided insights into its subsidiary OriGene Technologies, Inc. (OTI), highlighting its primary operations in the United States and a smaller presence in Germany [2] Group 1: Company Operations - OTI's main operational base is in the United States, focusing on the sale of research reagents [2] - The subsidiary in Germany contributes a minor portion to the overall revenue of the company [2]

Group 1 - The core point of the article is that Zhongyuan Qihhe (600645.SH) has a subsidiary, OriGene Technologies, Inc. (OTI), which primarily operates in the United States and has established a subsidiary in Germany [2] - OTI's overseas sales of research reagents are mainly focused on the U.S. market, while the German subsidiary contributes a relatively small proportion to the company's overall revenue [2]

Group 1 - The core viewpoint of the news is that Zhongyuan Xiehe's stock has shown a positive trend with a 10.16% increase year-to-date and a market capitalization of 12.99 billion yuan as of January 12 [1] - The company operates in the medical and biological industry, specifically in the field of medical devices and in vitro diagnostics, with a revenue composition primarily from testing reagents (58.46%) and cell detection preparation and storage (26.49%) [1][2] - As of September 30, 2025, Zhongyuan Xiehe reported a revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] Group 2 - The company has not distributed any dividends in the last three years, with a total payout of 37.54 million yuan since its A-share listing [3] - As of September 30, 2025, the number of shareholders increased by 4.06% to 34,700, while the average circulating shares per person decreased by 3.91% to 13,482 shares [2][3] - Major shareholders include Hong Kong Central Clearing Limited, which holds 15.25 million shares, an increase of 902,300 shares compared to the previous period [3]

Group 1 - The core viewpoint of the news is that Zhongyuan Qihua's stock has shown a slight increase of 2.02% recently, with a current trading price of 25.71 yuan per share and a total market capitalization of 12.031 billion yuan [1] - As of September 30, 2025, Zhongyuan Qihua reported a revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] - The company's main business revenue composition includes 58.46% from testing reagents, 26.49% from cell detection preparation and storage, 11.86% from research reagents, 2.40% from genetic testing, and 0.79% from other sources [1] Group 2 - Zhongyuan Qihua operates in the medical biology sector, specifically in medical devices and in vitro diagnostics, with concepts including stem cells, assisted reproduction, biomedicine, cancer treatment, and innovative drugs [2] - The number of shareholders for Zhongyuan Qihua increased by 4.06% to 34,700 as of September 30, 2025, while the average circulating shares per person decreased by 3.91% to 13,482 shares [2] - The company has not distributed any dividends in the last three years, with a total payout of 37.5405 million yuan since its A-share listing [3]

Group 1 - The company has completed all dosing for the Phase I clinical trial of VUM02 for the treatment of idiopathic pulmonary fibrosis (IPF) [2] - The company is currently organizing clinical safety and efficacy data following the completion of the Phase I trial [2] - Future updates regarding the clinical trial progress will be provided through company announcements and regular reports [2]

证券代码：600645 证券简称：中源协和 公告编号：2025-058 中源协和细胞基因工程股份有限公司 关于使用暂时闲置募集资金进行现金管理的进展公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）投资目的 为提高资金使用效率，在不影响募集资金投资项目建设和公司正常经营的情 况下，公司拟使用部分闲置募集资金进行现金管理，可以增加资金收益，为公司 重要内容提示： ●现金管理受托方：华夏银行股份有限公司上海分行 ●现金管理产品名称：人民币单位结构性存款 2511201 ●现金管理金额：1.2 亿元 ●现金管理期限：92 天 ●履行的审议程序：公司于 2025 年 12 月 25 日召开十一届二十四次临时董 事会会议，审议通过了《关于使用暂时闲置的募集资金进行现金管理及自有资金 进行委托理财的议案》。在不影响募集资金投资项目建设和公司正常经营的情况 下，同意公司使用不超过人民币 1.2 亿元的闲置募集资金进行现金管理，自公司 董事会审议通过之日起 12 个月内有效，在审批期限与授权额度内，资金可循环 滚动使用。 ●特别风 ...